Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Stomach Neoplasms 8Colorectal Neoplasms 7Pancreatic Neoplasms 5Ovarian Neoplasms 5Neoplasm Metastasis 5Melanoma 5Esophageal Neoplasms 4Uterine Cervical Neoplasms 3Rectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Vaginal Neoplasms 2Sarcoma 2Penile Neoplasms 2Oropharyngeal Neoplasms 2Mesothelioma 2Lung Neoplasms 2Liver Neoplasms 2Hodgkin Disease 2Head and Neck Neoplasms 2Carcinoma, Hepatocellular 2Carcinoma 2Breast Neoplasms 2Anus Neoplasms 2Wilms Tumor 1Turcot syndrome 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1

Interventions

fludarabine phosphate 1fludarabine 1entinostat 1aldesleukin 1Thalidomide 1Radiotherapy, Image-Guided 1Psychiatric Rehabilitation 1Fentanyl 1Docetaxel 1Cyclophosphamide 1Bariatric Surgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningioma × fludarabine phosphate × Gastrointestinal × Clear all
NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 12 charts
BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡